Exact Sciences Corporation (EXAS)

US — Healthcare Sector
Peers: GH  ICLR  VTRS  BBIO  SMMT  RVTY  ROIV  RVMD  DOCS  QGEN 

Automate Your Wheel Strategy on EXAS

With Tiblio's Option Bot, you can configure your own wheel strategy including EXAS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Why Investors Need to Take Advantage of These 2 Medical Stocks Now
EXAS, HRTX
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Read More
image for news Why Investors Need to Take Advantage of These 2 Medical Stocks Now
3 Top Cancer Biotechs to Keep An Eye On in 2025
EXAS, GLUE, NVS
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Neutral

If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.

Read More
image for news 3 Top Cancer Biotechs to Keep An Eye On in 2025
2 Stocks Down 59% and 34% to Buy and Hold
ETSY, EXAS
Published: February 24, 2025 by: The Motley Fool
Sentiment: Positive

Warren Buffett, arguably the greatest investor of all time, once said it is wise for investors to be fearful when others are greedy. One way to apply this advice from the Oracle of Omaha is to look at a soaring stock market and identify companies that aren't performing nearly as well -- or are just performing poorly -- but still have attractive prospects.

Read More
image for news 2 Stocks Down 59% and 34% to Buy and Hold
Exact Sciences: A Strong Q4 Reveals Signs Of A Potential Inflection Point
EXAS
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Positive

Exact Sciences posted strong Q4 revenue growth but faced a significant EPS miss due to an $838M impairment charge from the Thrive acquisition. Despite the negative market reaction, Exact's core business shows momentum, with strong demand for Cologuard and a solid cash position of $1.04B. The company has ambitious 2025 revenue guidance and expects new product launches to drive growth, aiming for sustained profitability and long-term value.

Read More
image for news Exact Sciences: A Strong Q4 Reveals Signs Of A Potential Inflection Point
Exact Sciences Corporation (EXAS) Q4 2024 Earnings Call Transcript
EXAS
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral

Exact Sciences Corporation (NASDAQ:EXAS ) Q4 2024 Earnings Conference Call February 19, 2025 5:00 PM ET Company Participants Derek Leckow - Vice President, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Aaron Bloomer - Chief Financial Officer Brian Baranick - General Manager, Precision Oncology Conference Call Participants Catherine Schulte - Baird Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Jack Meehan - Nephron Research Andrew Brackmann - William Blair Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Subu Nambi - Guggenheim Securities Puneet Souda - Leerink …

Read More
image for news Exact Sciences Corporation (EXAS) Q4 2024 Earnings Call Transcript
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
EXAS
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Negative

Exact Sciences (EXAS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.27 per share a year ago.

Read More
image for news Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates

About Exact Sciences Corporation (EXAS)

  • IPO Date 2001-02-01
  • Website https://www.exactsciences.com
  • Industry Medical - Diagnostics & Research
  • CEO Kevin T. Conroy
  • Employees 6900
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.